KLK7 expression in human tumors: a tissue microarray study on 13,447 tumors.

Humans Kallikreins / metabolism Tissue Array Analysis Neoplasms / pathology Biomarkers, Tumor / metabolism Female Immunohistochemistry Male

Immunohistochemistry KLK7 Neoplastic human tissues Tissue microarray

Journal

BMC cancer

ISSN: 1471-2407

Titre abrégé: BMC Cancer

Pays: England

ID NLM: 100967800

Informations de publication

Date de publication:
03 Jul 2024

Historique:

received: 26 10 2022

accepted: 23 06 2024

medline: 4 7 2024

pubmed: 4 7 2024

entrez: 3 7 2024

Statut: epublish

Résumé

Kallikrein-related peptidase 7 (KLK7) is a chymotrypsin-like serine protease which is essential for the desquamation of corneocytes and thus plays a pivotal role in maintaining skin homeostasis. In cancer, KLK7 overexpression was suggested to represent a route for metastasis through cleavage of cell junction and extracellular matrix proteins of cancer cells. To comprehensively determine KLK7 protein expression in normal and neoplastic tissues, a tissue microarray containing 13,447 samples from 147 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. KLK7 positivity was found in 64 of 147 tumor categories, including 17 tumor categories with at least one strongly positive case. The highest rate of KLK7 positivity was found in squamous cell carcinomas from various sites of origin (positive in 18.1%-63.8%), ovarian and endometrium cancers (4.8%-56.2%), salivary gland tumors (4.8%-13.7%), bilio-pancreatic adenocarcinomas (20.0%-40.4%), and adenocarcinomas of the upper gastrointestinal tract (3.3%-12.5%). KLK7 positivity was linked to nodal metastasis (p = 0.0005), blood vessel infiltration (p = 0.0037), and lymph vessel infiltration (p < 0.0001) in colorectal adenocarcinoma, nodal metastasis in hepatocellular carcinoma (p = 0.0382), advanced pathological tumor stage in papillary thyroid cancer (p = 0.0132), and low grade of malignancy in a cohort of 719 squamous cell carcinomas from 11 different sites of origin (p < 0.0001). These data provide a comprehensive overview on KLK7 expression in normal and neoplastic human tissues. The prognostic relevance of KLK7 expression and the possible role of KLK7 as a drug target need to be further investigated.

Sections du résumé

BACKGROUND BACKGROUND

METHODS METHODS

To comprehensively determine KLK7 protein expression in normal and neoplastic tissues, a tissue microarray containing 13,447 samples from 147 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry.

RESULTS RESULTS

KLK7 positivity was found in 64 of 147 tumor categories, including 17 tumor categories with at least one strongly positive case. The highest rate of KLK7 positivity was found in squamous cell carcinomas from various sites of origin (positive in 18.1%-63.8%), ovarian and endometrium cancers (4.8%-56.2%), salivary gland tumors (4.8%-13.7%), bilio-pancreatic adenocarcinomas (20.0%-40.4%), and adenocarcinomas of the upper gastrointestinal tract (3.3%-12.5%). KLK7 positivity was linked to nodal metastasis (p = 0.0005), blood vessel infiltration (p = 0.0037), and lymph vessel infiltration (p < 0.0001) in colorectal adenocarcinoma, nodal metastasis in hepatocellular carcinoma (p = 0.0382), advanced pathological tumor stage in papillary thyroid cancer (p = 0.0132), and low grade of malignancy in a cohort of 719 squamous cell carcinomas from 11 different sites of origin (p < 0.0001).

CONCLUSIONS CONCLUSIONS

These data provide a comprehensive overview on KLK7 expression in normal and neoplastic human tissues. The prognostic relevance of KLK7 expression and the possible role of KLK7 as a drug target need to be further investigated.

Identifiants

DOI: 10.1186/s12885-024-12552-8 PMID: 38961454

pubmed: 38961454

doi: 10.1186/s12885-024-12552-8

pii: 10.1186/s12885-024-12552-8

doi:

Substances chimiques

Kallikreins EC 3.4.21.-

KLK7 protein, human EC 3.4.21.-

Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

794

Informations de copyright

Références

Clements J, Hooper J, Dong Y, Harvey T. The expanded human kallikrein (KLK) gene family: genomic organisation, tissue-specific expression and potential functions. Biol Chem. 2001;382(1):5–14.

pubmed: 11258672 doi: 10.1515/BC.2001.002

Hong SK. Kallikreins as biomarkers for prostate cancer. Biomed Res Int. 2014;2014:526341.

pubmed: 24809052 pmcid: 3997884 doi: 10.1155/2014/526341

Avgeris M, Mavridis K, Scorilas A. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. Biol Chem. 2012;393(5):301–17.

pubmed: 22505514 doi: 10.1515/hsz-2011-0260

Yousef GM, Scorilas A, Magklara A, Soosaipillai A, Diamandis EP. The KLK7 (PRSS6) gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family - genomic characterization, mapping, tissue expression and hormonal regulation. Gene. 2000;254(1–2):119–28.

pubmed: 10974542 doi: 10.1016/S0378-1119(00)00280-8

Caubet C, Jonca N, Brattsand M, Guerrin M, Bernard D, Schmidt R, Egelrud T, Simon M, Serre G. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J Invest Dermatol. 2004;122(5):1235–44.

pubmed: 15140227 doi: 10.1111/j.0022-202X.2004.22512.x

de Veer SJ, Furio L, Swedberg JE, Munro CA, Brattsand M, Clements JA, Hovnanian A, Harris JM. Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7) Shed Light on KLK Proteolytic Activity in the Stratum Corneum. J Invest Dermatol. 2017;137(2):430–9.

pubmed: 27697464 doi: 10.1016/j.jid.2016.09.017

Hansson L, Strömqvist M, Bäckman A, Wallbrandt P, Carlstein A, Egelrud T. Cloning, expression, and characterization of stratum corneum chymotryptic enzyme. A skin-specific human serine proteinase. J Biol Chem. 1994;269(30):19420–6.

pubmed: 8034709 doi: 10.1016/S0021-9258(17)32185-3

Levi K, Baxter J, Meldrum H, Misra M, Pashkovski E, Dauskardt RH. Effect of corneodesmosome degradation on the intercellular delamination of human stratum corneum. J Invest Dermatol. 2008;128(9):2345–7.

pubmed: 18449214 doi: 10.1038/jid.2008.107

Kishibe M. Physiological and pathological roles of kallikrein-related peptidases in the epidermis. J Dermatol Sci. 2019;95(2):50–5.

pubmed: 31279501 doi: 10.1016/j.jdermsci.2019.06.007

Iakovlev V, Siegel ER, Tsao MS, Haun RS. Expression of kallikrein-related peptidase 7 predicts poor prognosis in patients with unresectable pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2012;21(7):1135–42.

pubmed: 22573795 doi: 10.1158/1055-9965.EPI-11-1079

Johnson SK, Ramani VC, Hennings L, Haun RS. Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E-cadherin. Cancer. 2007;109(9):1811–20.

pubmed: 17354228 doi: 10.1002/cncr.22606

Shigemasa K, Tanimoto H, Underwood LJ, Parmley TH, Arihiro K, Ohama K, O’Brien TJ. Expression of the protease inhibitor antileukoprotease and the serine protease stratum corneum chymotryptic enzyme (SCCE) is coordinated in ovarian tumors. Int J Gynecol Cancer. 2001;11(6):454–61.

pubmed: 11906548 doi: 10.1136/ijgc-00009577-200111000-00005

Wang P, Magdolen V, Seidl C, Dorn J, Drecoll E, Kotzsch M, Yang F, Schmitt M, Schilling O, Rockstroh A, et al. Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer. Br J Cancer. 2018;119(7):1–9.

pubmed: 30287916 pmcid: 6189062 doi: 10.1038/s41416-018-0260-1

Dorn J, Gkazepis A, Kotzsch M, Kremer M, Propping C, Mayer K, Mengele K, Diamandis EP, Kiechle M, Magdolen V, et al. Clinical value of protein expression of kallikrein-related peptidase 7 (KLK7) in ovarian cancer. Biol Chem. 2014;395(1):95–107.

pubmed: 23999494 doi: 10.1515/hsz-2013-0172

Xuan Q, Yang X, Mo L, Huang F, Pang Y, Qin M, Chen Z, He M, Wang Q, Mo ZN. Expression of the serine protease kallikrein 7 and its inhibitor antileukoprotease is decreased in prostate cancer. Arch Pathol Lab Med. 2008;132(11):1796–801.

pubmed: 18976018 doi: 10.5858/132.11.1796

Zhang CY, Zhu Y, Rui WB, Dai J, Shen ZJ. Expression of kallikrein-related peptidase 7 is decreased in prostate cancer. Asian J Androl. 2015;17(1):106–10.

pubmed: 25219913 doi: 10.1002/asia.201402962

Geng X, Babayeva L, Walch A, Aubele M, Groß E, Kiechle M, Bronger H, Dreyer T, Magdolen V, Dorn J. High levels of KLK7 protein expression are related to a favorable prognosis in triple-negative breast cancer patients. Am J Cancer Res. 2020;10(6):1785–92.

pubmed: 32642290 pmcid: 7339269

Santin AD, Cane’ S, Bellone S, Bignotti E, Palmieri M, De Las Casas LE, Roman JJ, Anfossi S, O’Brien T, Pecorelli S. The serine protease stratum corneum chymotryptic enzyme (kallikrein 7) is highly overexpressed in squamous cervical cancer cells. Gynecol Oncol. 2004;94(2):283–8.

pubmed: 15297163 doi: 10.1016/j.ygyno.2004.05.023

Delaunay T, Deschamps L, Haddada M, Walker F, Soosaipillai A, Soualmia F, El Amri C, Diamandis EP, Brattsand M, Magdolen V, et al. Aberrant expression of kallikrein-related peptidase 7 is correlated with human melanoma aggressiveness by stimulating cell migration and invasion. Mol Oncol. 2017;11(10):1330–47.

pubmed: 28636767 pmcid: 5623816 doi: 10.1002/1878-0261.12103

Kumar DV, Sivaranjani Y, Rao GV. Immunohistochemical expression of kallikrein 7 in oral squamous cell carcinoma. J Oral Maxillofac Pathol. 2020;24(3):580.

pubmed: 33967508 doi: 10.4103/jomfp.JOMFP_244_19

Walker F, Nicole P, Jallane A, Soosaipillai A, Mosbach V, Oikonomopoulou K, Diamandis EP, Magdolen V, Darmoul D. Kallikrein-related peptidase 7 (KLK7) is a proliferative factor that is aberrantly expressed in human colon cancer. Biol Chem. 2014;395(9):1075–86.

pubmed: 25153388 doi: 10.1515/hsz-2014-0142

Pettus JR, Johnson JJ, Shi Z, Davis JW, Koblinski J, Ghosh S, Liu Y, Ravosa MJ, Frazier S, Stack MS. Multiple kallikrein (KLK 5, 7, 8, and 10) expression in squamous cell carcinoma of the oral cavity. Histol Histopathol. 2009;24(2):197–207.

pubmed: 19085836 pmcid: 2835693

Termini L, Maciag PC, Soares FA, Nonogaki S, Pereira SM, Alves VA, Longatto-Filho A, Villa LL. Analysis of human kallikrein 7 expression as a potential biomarker in cervical neoplasia. Int J Cancer. 2010;127(2):485–90.

pubmed: 19921697 doi: 10.1002/ijc.25046

Tian X, Shigemasa K, Hirata E, Gu L, Uebaba Y, Nagai N, O’Brien TJ, Ohama K. Expression of human kallikrein 7 (hK7/SCCE) and its inhibitor antileukoprotease (ALP/SLPI) in uterine endocervical glands and in cervical adenocarcinomas. Oncol Rep. 2004;12(5):1001–6.

pubmed: 15492784

Zhao H, Dong Y, Quan J, Smith R, Lam A, Weinstein S, Clements J, Johnson NW, Gao J. Correlation of the expression of human kallikrein-related peptidases 4 and 7 with the prognosis in oral squamous cell carcinoma. Head Neck. 2011;33(4):566–72.

pubmed: 20665732 doi: 10.1002/hed.21496

Leusink FK, van Diest PJ, Frank MH, Broekhuizen R, Braunius W, van Hooff SR, Willems SM, Koole R. The Co-Expression of Kallikrein 5 and Kallikrein 7 Associates with Poor Survival in Non-HPV Oral Squamous-Cell Carcinoma. Pathobiology. 2015;82(2):58–67.

pubmed: 26022646 doi: 10.1159/000381904

Gabril M, White NM, Moussa M, Chow TF, Metias SM, Fatoohi E, Yousef GM. Immunohistochemical analysis of kallikrein-related peptidases in the normal kidney and renal tumors: potential clinical implications. Biol Chem. 2010;391(4):403–9.

pubmed: 20128686 doi: 10.1515/bc.2010.025

Xiang F, Wang Y, Cao C, Li Q, Deng H, Zheng J, Liu X, Tan X. The Role of Kallikrein 7 in Tumorigenesis. Curr Med Chem. 2022;29(15):2617–31.

pubmed: 34525904 doi: 10.2174/0929867328666210915104537

Rico SD, Mahnken M, Buscheck F, Dum D, Luebke AM, Kluth M, Hube-Magg C, Hinsch A, Hoflmayer D, Moller-Koop C, et al. MUC5AC Expression in Various Tumor Types and Nonneoplastic Tissue: A Tissue Microarray Study on 10 399 Tissue Samples. Technol Cancer Res Treat. 2021;20:15330338211043328.

pubmed: 34547930 pmcid: 8461123 doi: 10.1177/15330338211043328

Steurer S, Riemann C, Buscheck F, Luebke AM, Kluth M, Hube-Magg C, Hinsch A, Hoflmayer D, Weidemann S, Fraune C, et al. p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors. Biomark Res. 2021;9(1):7.

pubmed: 33494829 pmcid: 7830855 doi: 10.1186/s40364-021-00260-5

Uhlig R, Gunther K, Broker N, Gorbokon N, Lennartz M, Dwertmann Rico S, Reiswich V, Viehweger F, Buscheck F, Kluth M, et al. Diagnostic and prognostic role of pancreatic secretory granule membrane major glycoprotein 2 (GP2) immunohistochemistry: A TMA study on 27,681 tumors. Pathol Res Pract. 2022;238:154123.

pubmed: 36137400 doi: 10.1016/j.prp.2022.154123

Bubendorf L, Nocito A, Moch H, Sauter G. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol. 2001;195(1):72–9.

pubmed: 11568893 doi: 10.1002/path.893

Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4(7):844–7.

pubmed: 9662379 doi: 10.1038/nm0798-844

Uhlen M, Bandrowski A, Carr S, Edwards A, Ellenberg J, Lundberg E, Rimm DL, Rodriguez H, Hiltke T, Snyder M, et al. A proposal for validation of antibodies. Nat Methods. 2016;13(10):823–7.

pubmed: 27595404 pmcid: 10335836 doi: 10.1038/nmeth.3995

Lizio M, Harshbarger J, Shimoji H, Severin J, Kasukawa T, Sahin S, Abugessaisa I, Fukuda S, Hori F, Ishikawa-Kato S, et al. Gateways to the FANTOM5 promoter level mammalian expression atlas. Genome Biol. 2015;16:22.

pubmed: 25723102 pmcid: 4310165 doi: 10.1186/s13059-014-0560-6

Lizio M, Harshbarger J, Abugessaisa I, Noguchi S, Kondo A, Severin J, Mungall C, Arenillas D, Mathelier A, Medvedeva YA, et al. Update of the FANTOM web resource: high resolution transcriptome of diverse cell types in mammals. Nucleic Acids Res. 2017;45(D1):D737–43.

pubmed: 27794045 doi: 10.1093/nar/gkw995

Consortium G. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45(6):580–5.

doi: 10.1038/ng.2653

Karlsson M, Zhang C, Méar L, Zhong W, Digre A, Katona B, Sjöstedt E, Butler L, Odeberg J, Dusart P, et al. A single-cell type transcriptomics map of human tissues. Sci Adv. 2021;7(31):eabh2169.

pubmed: 34321199 pmcid: 8318366 doi: 10.1126/sciadv.abh2169

Yousef GM, Yacoub GM, Polymeris ME, Popalis C, Soosaipillai A, Diamandis EP. Kallikrein gene downregulation in breast cancer. Br J Cancer. 2004;90(1):167–72.

pubmed: 14710225 pmcid: 2395319 doi: 10.1038/sj.bjc.6601451

Li X, Liu J, Wang Y, Zhang L, Ning L, Feng Y. Parallel underexpression of kallikrein 5 and kallikrein 7 mRNA in breast malignancies. Cancer Sci. 2009;100(4):601–7.

pubmed: 19453546 pmcid: 11158435 doi: 10.1111/j.1349-7006.2009.01090.x

Talieri M, Diamandis EP, Gourgiotis D, Mathioudaki K, Scorilas A. Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. Thromb Haemost. 2004;91(1):180–6.

pubmed: 14691584 doi: 10.1160/TH03-05-0261

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.

pubmed: 22588877 doi: 10.1158/2159-8290.CD-12-0095

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.

pubmed: 23550210 pmcid: 4160307 doi: 10.1126/scisignal.2004088

Okegawa T, Pong RC, Li Y, Hsieh JT. The role of cell adhesion molecule in cancer progression and its application in cancer therapy. Acta Biochim Pol. 2004;51(2):445–57.

pubmed: 15218541 doi: 10.18388/abp.2004_3583

Kramer IR, Lucas RB, Pindborg JJ, Sobin LH. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol. 1978;46(4):518–39.

pubmed: 280847 doi: 10.1016/0030-4220(78)90383-3

van Harten AM, Brakenhoff RH. Targeted Treatment of Head and Neck (Pre) Cancer: Preclinical Target Identification and Development of Novel Therapeutic Applications. Cancers (Basel). 2021;13(11):2774.

pubmed: 34204886 doi: 10.3390/cancers13112774

Taggart MW, Rashid A, Ross WA, Abraham SC. Oesophageal hyperkeratosis: clinicopathological associations. Histopathology. 2013;63(4):463–73.

pubmed: 23879628 doi: 10.1111/his.12195

Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015;10(9):1243–60.

pubmed: 26291008 doi: 10.1097/JTO.0000000000000630

Uhlig R, Abboud M, Gorbokon N, Lennartz M, Dwertmann Rico S, Kind S, Reiswich V, Viehweger F, Kluth M, Hube-Magg C, et al. Cytokeratin 10 (CK10) expression in cancer: A tissue microarray study on 11,021 tumors. Ann Diagn Pathol. 2022;60:152029.

pubmed: 36029589 doi: 10.1016/j.anndiagpath.2022.152029

Silva LM, Kryza T, Stoll T, Hoogland C, Dong Y, Stephens CR, Hastie ML, Magdolen V, Kleifeld O, Gorman JJ, et al. Integration of Two In-depth Quantitative Proteomics Approaches Determines the Kallikrein-related Peptidase 7 (KLK7) Degradome in Ovarian Cancer Cell Secretome. Mol Cell Proteomics. 2019;18(5):818–36.

pubmed: 30705123 pmcid: 6495248 doi: 10.1074/mcp.RA118.001304

Ramani VC, Hennings L, Haun RS. Desmoglein 2 is a substrate of kallikrein 7 in pancreatic cancer. BMC Cancer. 2008;8:373.

pubmed: 19091121 pmcid: 2628383 doi: 10.1186/1471-2407-8-373

Yu Y, Prassas I, Dimitromanolakis A, Diamandis EP. Novel Biological Substrates of Human Kallikrein 7 Identified through Degradomics. J Biol Chem. 2015;290(29):17762–75.

pubmed: 26032414 pmcid: 4505025 doi: 10.1074/jbc.M115.643551

Ramani VC, Haun RS. Expression of kallikrein 7 diminishes pancreatic cancer cell adhesion to vitronectin and enhances urokinase-type plasminogen activator receptor shedding. Pancreas. 2008;37(4):399–404.

pubmed: 18953252 doi: 10.1097/MPA.0b013e31817f76f7

Mo L, Zhang J, Shi J, Xuan Q, Yang X, Qin M, Lee C, Klocker H, Li QQ, Mo Z. Human kallikrein 7 induces epithelial-mesenchymal transition-like changes in prostate carcinoma cells: a role in prostate cancer invasion and progression. Anticancer Res. 2010;30(9):3413–20.

pubmed: 20944116

Ramani VC, Haun RS. The extracellular matrix protein fibronectin is a substrate for kallikrein 7. Biochem Biophys Res Commun. 2008;369(4):1169–73.

pubmed: 18343220 doi: 10.1016/j.bbrc.2008.03.021

Wong SHM, Fang CM, Chuah LH, Leong CO, Ngai SC. E-cadherin: Its dysregulation in carcinogenesis and clinical implications. Crit Rev Oncol Hematol. 2018;121:11–22.

pubmed: 29279096 doi: 10.1016/j.critrevonc.2017.11.010

Bazzazi H, Zhang Y, Jafarnejad M, Isenberg JS, Annex BH, Popel AS. Computer Simulation of TSP1 Inhibition of VEGF-Akt-eNOS: An Angiogenesis Triple Threat. Front Physiol. 2018;9:644.

pubmed: 29899706 pmcid: 5988849 doi: 10.3389/fphys.2018.00644

Bussolati B, Assenzio B, Deregibus MC, Camussi G. The proangiogenic phenotype of human tumor-derived endothelial cells depends on thrombospondin-1 downregulation via phosphatidylinositol 3-kinase/Akt pathway. J Mol Med (Berl). 2006;84(10):852–63.

pubmed: 16924472 doi: 10.1007/s00109-006-0075-z

Bach LA. What Happened to the IGF Binding Proteins? Endocrinology. 2018;159(2):570–8.

pubmed: 29165552 doi: 10.1210/en.2017-00908

Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20(2):74–88.

pubmed: 31686003 doi: 10.1038/s41568-019-0216-7

Ramani VC, Kaushal GP, Haun RS. Proteolytic action of kallikrein-related peptidase 7 produces unique active matrix metalloproteinase-9 lacking the C-terminal hemopexin domains. Biochim Biophys Acta. 2011;1813(8):1525–31.

pubmed: 21616098 pmcid: 3123393 doi: 10.1016/j.bbamcr.2011.05.007

Davidson B, Reich R, Risberg B, Nesland JM. The biological role and regulation of matrix metalloproteinases (MMP) in cancer. Arkh Patol. 2002;64(3):47–53.

pubmed: 15338725

Sauter G. Representativity of TMA studies. Methods Mol Biol. 2010;664:27–35.

pubmed: 20690049 doi: 10.1007/978-1-60761-806-5_3

Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol. 2001;159(6):2249–56.

pubmed: 11733374 pmcid: 1850582 doi: 10.1016/S0002-9440(10)63075-1

Du JP, Li L, Zheng J, Zhang D, Liu W, Zheng WH, Li XS, Yao RC, Wang F, Liu S, et al. Kallikrein-related peptidase 7 is a potential target for the treatment of pancreatic cancer. Oncotarget. 2018;9(16):12894–906.

pubmed: 29560118 pmcid: 5849182 doi: 10.18632/oncotarget.24132